Published on: 2026-04-08
Updated on: 2026-04-08
Eli Lilly remains the top healthcare stock for 2026 after 56% Q1 revenue growth, a $2 billion guidance raise, and FDA approval for its oral GLP-1 pill.
Intuitive Surgical leads medical-device growth, with Q1 revenue up 23%, da Vinci procedure volume up about 16%, and Ion procedure volume up about 39%.
Large-cap pharma offers the best risk-adjusted base. Merck, AbbVie, Vertex, and Regeneron combine durable cash flow with oncology, immunology, and rare-disease pipelines.
Healthcare services remain defensive but slower growing. UnitedHealth posted $111.7 billion in Q1 revenue and raised 2026 adjusted EPS guidance above $18.25.
Tempus has the strongest AI healthcare setup. Revenue rose 36.1% to $348.1 million, with diagnostics revenue up 34.7% and data/applications revenue up 40.5%.
Viking and Recursion are high-risk growth names. Their upside depends more on clinical execution, capital discipline, and platform validation than current earnings.
Healthcare stocks cover companies that develop drugs, run hospitals, sell medical devices, manage insurance plans, or build diagnostics and health technology platforms. The best names are not simply defensive. They have approved products, pricing power, recurring demand, strong trial data, or scale that can convert medical need into earnings growth.
Aging populations, chronic disease, obesity treatment demand, and hospital cost pressure are pushing medical spending toward companies with proven scale and approved products. Lilly’s 56% Q1 revenue growth, Intuitive Surgical’s 23% revenue increase, UnitedHealth’s $111.7 billion quarterly revenue, and Tempus AI’s 36.1% growth show where the market is rewarding execution. Obesity drugs, robotic surgery, oncology, immunology, managed care, and AI diagnostics are now the clearest growth channels in the sector.
| Rank | Company | Ticker | Category | Brief investment case |
|---|---|---|---|---|
| 1 | Eli Lilly | LLY | Biopharma / Obesity & Diabetes | Market leader in GLP-1 growth, with 56% Q1 revenue growth, a $2 billion guidance raise, and added support from oral GLP-1 approval. |
| 2 | Intuitive Surgical | ISRG | Medical Devices / Robotic Surgery | Robotic-surgery leader with Q1 revenue up 23% and combined da Vinci and Ion procedures up about 17%. |
| 3 | Vertex Pharmaceuticals | VRTX | Biotech / Rare Disease & Specialty Drugs | High-margin biotech with approved rare-disease franchises and pipeline depth beyond cystic fibrosis. |
| 4 | Novo Nordisk | NVO | Biopharma / Obesity & Diabetes | Core obesity and diabetes compounder, though growth is now judged against Lilly’s faster GLP-1 momentum. |
| 5 | Merck | MRK | Large-Cap Pharma / Oncology | Keytruda remains a major oncology cash-flow engine, with pipeline execution needed to offset patent-cycle risk. |
| 6 | Abbott Laboratories | ABT | Medical Devices / Diagnostics | Diversified healthcare exposure across diabetes care, cardiovascular devices, diagnostics, and nutrition. |
| 7 | AbbVie | ABBV | Large-Cap Pharma / Immunology | Skyrizi and Rinvoq support the post-Humira transition, keeping AbbVie relevant for income and immunology growth. |
| 8 | Stryker | SYK | Medical Devices / Orthopaedics & Surgical Equipment | Strong long-term medtech demand, but Q1 performance was affected by slower organic growth, EPS pressure, and cyber-related disruption. (BigGo Finance) |
| 9 | Regeneron Pharmaceuticals | REGN | Biotech / Ophthalmology & Immunology | Profitable biotech with durable ophthalmology exposure and expanding oncology and immunology optionality. |
| 10 | UnitedHealth Group | UNH | Managed Care / Healthcare Services | Scale leader in insurance and health services, but margin scrutiny and utilisation costs remain key risks. |
| 11 | HCA Healthcare | HCA | Healthcare Services / Hospitals | Hospital operator with scale advantages, admissions leverage, and direct exposure to US care demand. |
| 12 | Tempus AI | TEM | AI Diagnostics / Health Tech | Strongest AI healthcare setup in the list, with Q1 revenue up 36.1% and growth across diagnostics and data applications. (Tempus) |
| 13 | Viking Therapeutics | VKTX | Clinical-Stage Biotech / Obesity & Metabolic Disease | High-upside obesity biotech tied to VK2735 clinical execution rather than current earnings. |
| 14 | Recursion Pharmaceuticals | RXRX | AI Drug Discovery / Platform Biotech | Speculative AI drug-discovery platform where upside depends on clinical validation, partnerships, and cash discipline. |
Source: FDA approval announcements and company investor relations disclosures, including earnings releases and product updates, as of June 2026; author’s analysis.
Big Pharma remains the foundation of a healthcare portfolio offering the best combination of revenue visibility, balance-sheet strength, and commercial execution. In 2026, that matters most in obesity, immunology, and oncology. Lilly leads the group after 56% Q1 revenue growth and a $2 billion guidance raise, supported by both injectable GLP-1 demand and the newly approved oral category. Novo remains essential because obesity is still concentrated around two global leaders at scale, with Wegovy pill prescriptions surpassing 3 million and one prescription filled roughly every 5 seconds.
Merck belongs in this group but its appeal is less about explosive growth than franchise durability. KEYTRUDA QLEX strengthens administration convenience and helps extend the life of one of the most important oncology assets in the market. AbbVie rounds out the category as a large-cap recovery story that is increasingly defined by Skyrizi and Rinvoq rather than Humira erosion.
Stocks in this category: Eli Lilly, Novo Nordisk, Merck, AbbVie.
Medical devices rely less on binary drug approvals and more on procedure volumes, hospital productivity, and recurring utilisation. Intuitive Surgical and Abbott show that profile clearly: Intuitive’s Q1 revenue rose 23%, while Abbott’s Medical Devices sales grew 8.5% on a comparable basis.
Intuitive Surgical placed 431 da Vinci systems in Q1, including 232 da Vinci 5 systems, while da Vinci procedure volume rose 16% and Ion procedure volume rose 39%. Stryker still has long-term exposure to orthopaedics and Mako expansion, but Q1 showed execution pressure, with organic sales up only 2.4% and adjusted EPS down 8.5% after cyber-related disruption. Abbott on the other hand provides exposure to glucose monitoring, cardiovascular devices, diagnostics, and connected care in a single platform
Stocks in this category: Intuitive Surgical, Stryker, Abbott Laboratories.
Healthcare services, hospital operators, and diagnostics data platforms are where scale, patient volumes, reimbursement discipline, and ownership of healthcare infrastructure become investable advantages. UnitedHealth generated $111.7 billion in Q1 revenue, HCA reported $19.1 billion, and Tempus AI reached $348.1 million, showing three very different ways to monetise healthcare demand.
UnitedHealth is the scale and payor platform, with Q1 operating earnings of $9.0 billion and 2026 adjusted EPS guidance above $18.25. HCA is the hospital-volume platform, offering direct exposure to admissions, procedures, labour efficiency, and payer mix after Q1 revenue rose 4.3%. Tempus is the AI diagnostics and data platform: Q1 revenue grew 36.1%, diagnostics revenue reached $261.1 million, and data and applications revenue rose 40.5% to $87.0 million. Its tumor-only xT CDx FDA approval strengthens the commercial case beyond the AI narrative.
Stocks in this category: UnitedHealth Group, HCA Healthcare, Tempus AI.
Biotechnology is still where the most asymmetric upside resides, but it is also where stock selection matters most. The category spans profitable, established innovators and earlier-stage companies whose valuation depends heavily on future milestones rather than current earnings.
Vertex leads the group because it offers an unusually balanced profile: real profitability, strong execution, and an expanding pipeline. Q1 revenue rose 8% to $2.99 billion, and 2026 revenue guidance remains at $12.95 billion to $13.1 billion. Regeneron is the more commercially mature name, with Q1 revenue up 19% to $3.6 billion, but ophthalmology is in transition: EYLEA HD US sales rose 52%, while combined EYLEA HD and EYLEA US sales fell 10%.
Viking is the obesity challenger with the clearest speculative appeal, after VANQUISH-1 and VANQUISH-2 reached full enrolment and prior VK2735 Phase 2 data showed weight reduction of up to 14.7% after 13 weekly doses. Recursion remains the AI-enabled wildcard, but the risk is financial as well as clinical: 2026 operational cash burn is guided below $390 million, with runway into early 2028
Stocks in this category: Vertex Pharmaceuticals, Regeneron, Viking Therapeutics, and Recursion Pharmaceuticals.
Viking Therapeutics (VKTX): the most direct high-beta obesity idea outside Lilly and Novo. VANQUISH-1 and VANQUISH-2 are fully enrolled, but the thesis still depends on VK2735 Phase 3 execution.
Tempus AI (TEM): the most investable AI healthcare operating story. Q1 revenue rose 36.1% to $348.1 million, giving it stronger commercial proof than most healthcare AI names.
Recursion Pharmaceuticals (RXRX): an AI drug-discovery platform with meaningful upside, but heavy clinical and cash-burn risk. Management still guides for less than $390 million in 2026 operational cash burn, with runway into early 2028.
This risk split matters because high-beta healthcare names can move sharply around trial updates, approvals, and earnings revisions. EBC stock CFDs allow price exposure to selected healthcare leaders without owning the underlying shares, but position sizing matters more when volatility is driven by binary catalysts.
Obesity treatment remains the strongest theme because GLP-1 demand is moving from injectable drugs into oral formulations. Lilly’s Q1 revenue rose 56%, and the company raised 2026 revenue guidance by $2 billion after FDA approval for its oral GLP-1 pill.
Large-cap pharma and managed care remain the most defensive areas. Merck, AbbVie, and UnitedHealth offer stronger cash-flow visibility than clinical-stage biotech, while UnitedHealth’s $111.7 billion Q1 revenue shows the scale advantage in healthcare services.
Viking Therapeutics, Tempus AI, and Recursion carry the highest upside-risk balance. Viking depends on obesity trial execution, Tempus depends on AI diagnostics adoption and valuation discipline, and Recursion depends on clinical validation of its AI drug-discovery platform.
In many cases, yes. Medical-device companies benefit from procedure growth, chronic-disease monitoring, and hospital productivity. Intuitive Surgical’s Q1 revenue rose 23% to $2.77 billion, supported by higher procedure volume and da Vinci system placements.
Traders can use stock CFDs where available to gain price exposure without owning the underlying shares. This matters most for volatile healthcare names, where trial results, FDA decisions, earnings revisions, and guidance changes can move prices sharply.
The value of this ranking is not simply identifying 14 healthcare stocks for 2026. It separates them by portfolio role. Lilly, Intuitive Surgical, Vertex, Novo Nordisk, Merck, Abbott, and AbbVie sit closest to the core bucket because they combine scale, product demand, earnings visibility, and proven commercial execution.
For readers, the key takeaway is simple: healthcare stocks in 2026 should not be treated as one defensive sector trade. The strongest opportunities are split between large-cap pharma, medical devices, healthcare services, and selective biotech or AI healthcare names. Core holdings should be judged by revenue durability and execution. Speculative names should be judged by catalyst quality, cash runway, and downside risk.
Disclaimer: This material is for general information purposes only and is not intended as (and should not be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by EBC or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.
